Preliminary data from an ongoing trial of AstraZeneca's COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other varia
With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of
Preliminary study results from South Africa have suggested that antibodies stimulated by Pfizer and BioNTech's Comirnaty are less effective against the new COVID-19 variant Omicron.
A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body's T-cell immunity against the disease.
The Omicron variant could supersede other strains of COVID-19 within the next few weeks to become dominant in the UK, according to an infectious diseases expert.